Mounjaro vs Zepbound: Are They the Same Drug? (2026 Cost, Coverage & Switching Guide)

The short answer

Mounjaro and Zepbound are both tirzepatide, the dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Same active ingredient, same factories, same dosing strengths, same injection pen design. The only meaningful differences are the brand name on the box and the FDA-approved indication printed on the label.

Mounjaro was approved first (May 2022) for type 2 diabetes management.

Zepbound was approved later (November 2023) for chronic weight management in adults with obesity or overweight with weight-related comorbidities.

Pharmacologically, taking 5 mg of Mounjaro and 5 mg of Zepbound is identical. The molecules are the same, the pharmacokinetics are the same, the side effects are the same, and the effects on weight and glucose are the same. Anyone telling you otherwise — including some patient-confusion-driven discussion online — is mistaken about the underlying chemistry.

Why two names for one drug?

The pattern of one molecule under two brand names with different indications is common in pharmaceuticals. Several reasons drive it:

Regulatory clarity. The FDA approves drugs for specific indications. A diabetes drug approved for T2D management has labeling, marketing, and prescribing focused on that use case. Approving the same drug for a different population (people with obesity, regardless of T2D status) involves a separate FDA submission, separate Phase 3 trials, and a separate label. Different name reduces confusion about which population is which.

Payer separation. Insurance coverage operates on indication-specific approvals. A plan may cover diabetes medications but exclude obesity medications (or have different cost-sharing tiers, prior authorization requirements, or coverage criteria for each). Distinct brand names allow payers to maintain distinct coverage policies.

Marketing positioning. The marketing message for a diabetes drug ("better glycemic control with cardiovascular benefits") is different from the marketing message for an obesity drug ("substantial weight loss with metabolic benefits"). Separate names allow targeted marketing without confusing either patient population.

The same pattern applies elsewhere in the GLP-1 class: semaglutide is sold as Ozempic (T2D), Wegovy (obesity), and Rybelsus (oral T2D) — three names for what is fundamentally the same molecule with different delivery formats and indications.

Dosing: identical between the two

Both Mounjaro and Zepbound are available in the same dose strengths:

• 2.5 mg (starting/titration dose)
• 5 mg
• 7.5 mg
• 10 mg
• 12.5 mg
• 15 mg (maximum dose)

Both are once-weekly subcutaneous injections. Both use the same injector pen design. Both follow the same dose-escalation schedule — typically starting at 2.5 mg, escalating monthly by 2.5 mg increments until reaching the target therapeutic dose or maximum tolerability.

For diabetes, Mounjaro typical maintenance doses are 5-15 mg depending on glycemic response. For obesity, Zepbound typical maintenance doses are 5-15 mg depending on weight-loss response and tolerability. The maintenance dose tends to be higher in obesity contexts (more often at 10 or 15 mg) because weight loss benefits continue to scale with dose at the high end, whereas glycemic benefits plateau earlier.

Practical differences that aren't pharmacological

Several non-pharmacological differences may matter for individual patients:

Insurance coverage and cost. This is often the biggest practical difference. A patient with T2D may have full coverage for Mounjaro but only partial or no coverage for Zepbound. A patient with obesity but no diabetes may have the reverse. Cost-sharing tiers, prior authorization requirements, and step-therapy protocols (where insurance requires trying other drugs first) often differ between the two brand names.

Pharmacy stocking and availability. During the 2023-2024 tirzepatide shortage, Mounjaro and Zepbound experienced overlapping but not identical supply patterns — a pharmacy might have one in stock but not the other.

Prescribing context. An endocrinologist managing diabetes will typically prescribe Mounjaro; an obesity-medicine physician will typically prescribe Zepbound. Switching prescribers may switch the brand name even when the underlying medication doesn't change.

Compounding and substitution rules. The compounded-tirzepatide ecosystem has been substantially affected by FDA decisions through 2024-2025. The rules and availability differ in nuanced ways between the indications.

Can you switch between Mounjaro and Zepbound?

Pharmacologically, switching is trivial — same molecule, same dose. A patient who has been on Mounjaro 10 mg for diabetes management and gains an obesity diagnosis can be switched to Zepbound 10 mg without any titration, dose adjustment, or transition concerns. Effects continue uninterrupted because nothing actually changed except the label.

Insurance switches can be more complicated. A plan may require a new prior authorization or step-therapy review when switching brand names even if the molecule is the same. Patients sometimes report having to "re-justify" the medication when their indication or clinical context changes.

If your insurance covers one but not the other, talk to your prescriber about whether the other indication or brand name might fit your clinical picture in a way that aligns with coverage. This is a documentation and billing question rather than a clinical one.

Cost comparison in 2026: what you actually pay

List prices (Wholesale Acquisition Cost, what pharmacies pay before any discounts) for both Mounjaro and Zepbound are approximately the same — roughly $1,000-$1,100 for a 4-week supply, depending on dose strength. What patients pay out of pocket varies enormously:

• Commercial insurance with covered indication: Typically $25-$100/month copay if the medication is on formulary. Many plans use prior authorization, step therapy (requiring you try cheaper alternatives first), or quantity limits.
• Eli Lilly savings programs: Both Mounjaro and Zepbound have manufacturer savings cards that can reduce out-of-pocket cost substantially for eligible commercially-insured patients ($25-$150/month depending on coverage status).
• Cash pay / no insurance coverage: Direct-from-Lilly programs offer Zepbound vials (not pens) at $349-$499/month depending on dose — substantially below the pen list price. Available through LillyDirect.
• Medicare: Mounjaro covered when prescribed for diabetes; Zepbound coverage for obesity has been more limited but expanded through 2025-2026 under specific clinical criteria.
• Medicaid: Coverage varies substantially by state for both indications.

The honest practical reality: a patient with type 2 diabetes and commercial insurance often pays $25-100/month for Mounjaro; the same patient seeking Zepbound for obesity may face $500-1,000/month if obesity isn't a covered indication on their plan. The molecules are identical — the cost difference is purely coverage-driven.

What changed after the compounded tirzepatide resolution (2024-2025)

During the 2023-2024 tirzepatide shortage, compounding pharmacies were permitted to prepare compounded versions of tirzepatide under FDA discretion. This created an alternative access pathway for patients who couldn't get the branded product. The compounded tirzepatide market grew rapidly — telehealth companies, medspas, and traditional compounding pharmacies all participated.

As the FDA officially declared the tirzepatide shortage resolved in late 2024 / early 2025, the rules changed:

• 503B outsourcing facilities were given a wind-down period to stop producing compounded tirzepatide. Most have ceased production by mid-2026.
• 503A traditional compounding pharmacies retain narrower compounding authority for individual patient prescriptions where the compounded version is medically necessary (e.g., different concentration than commercial, different excipient for allergy reasons) — but routine "cheaper alternative to brand-name Zepbound" compounding is no longer permitted.
• The telehealth-compounded-tirzepatide market has substantially contracted. Several major operators stopped offering compounded tirzepatide entirely in 2025-2026; others pivoted to compounded semaglutide (which has its own ongoing regulatory landscape) or to brand-name prescribing.
• LillyDirect cash-pay pricing emerged as the primary alternative for patients without coverage — substantially cheaper than branded pens, though still more expensive than the compounded ecosystem was at its peak.

For patients currently on compounded tirzepatide, the practical question is: where do you go when your compounder stops producing it? The options are LillyDirect cash pay (for Zepbound vials), branded Zepbound or Mounjaro through insurance (with whatever cost-sharing your plan applies), or different medication entirely. See our compounded semaglutide vs brand-name Wegovy article for the parallel framework on the semaglutide side and the State of the Peptide Market 2026 article for the broader regulatory landscape.

Comparison table at a glance

Why the confusion exists

The two-names-for-one-drug pattern confuses many patients for understandable reasons:

Most consumers learn about prescription drugs through brand names rather than generic names. Mounjaro, Zepbound, Ozempic, and Wegovy are widely advertised; tirzepatide and semaglutide as molecule names are far less recognizable. When patients hear "Mounjaro for diabetes" and "Zepbound for weight loss" in separate marketing campaigns, the natural inference is that they're separate drugs.

Healthcare communication also typically uses brand names. Patients told "I'm starting you on Mounjaro" don't usually hear "which is tirzepatide, a dual GIP/GLP-1 agonist also marketed as Zepbound for obesity."

And the pricing experience reinforces the confusion — different copays, different coverage decisions, different pharmacy stocking patterns make the two feel like distinct products even though the medication is identical.

Understanding that they're the same drug clarifies several practical questions:

• If you've tolerated one, you'll tolerate the other (same molecule)
• If you've responded well to one, the other will work the same way
• "Should I switch from Mounjaro to Zepbound to lose more weight?" — the answer is no; the drug is the same. You'd need to address dose, adherence, or supporting interventions (nutrition, resistance training) instead.

Related questions readers often have

For comparisons across the broader GLP-1 brand-name landscape: Semaglutide vs Ozempic vs Wegovy vs Rybelsus (the semaglutide brand-name explainer), Byetta vs Bydureon (the exenatide brand-name story), and Liraglutide vs Semaglutide (the broader long-acting GLP-1 comparison).

For the actual drug comparison rather than brand-name comparison, see our Semaglutide vs Tirzepatide for Weight Loss article — that's the meaningful pharmacological comparison (tirzepatide vs semaglutide molecules) rather than the brand-name framing.

For the underlying tirzepatide pharmacology, see the Tirzepatide peptide page. For the emerging next-generation GLP-1 candidates — Retatrutide (triple agonist), MariTide (monthly dosing), and CagriSema (semaglutide + amylin combination) — see the per-compound coverage. For the Mounjaro and Zepbound side-effect timeline, see our GLP-1 Side Effects Week by Week guide.